CVS Health (NYSE:CVS) Shares Unloaded Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of CVS Health Co. NYSE: CVS. In a filing disclosed on May 31st, the Representative disclosed that they had sold between $1,001 and $15,000 in CVS Health stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
• Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
• Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
• Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
• Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
• Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.

CVS Health Stock Up 0.8%

CVS stock traded up $0.53 during trading on Friday, reaching $63.61. 3,264,199 shares of the stock were exchanged, compared to its average volume of 11,090,212. The firm's 50 day moving average is $65.30 and its 200 day moving average is $59.84. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $72.51. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. The firm has a market cap of $80.47 billion, a P/E ratio of 17.38, a price-to-earnings-growth ratio of 0.98 and a beta of 0.56.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same period last year, the business posted $1.31 earnings per share. CVS Health's revenue was up 7.0% on a year-over-year basis. As a group, research analysts forecast that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were given a dividend of $0.665 per share. The ex-dividend date was Tuesday, April 22nd. This represents a $2.66 annualized dividend and a dividend yield of 4.18%. CVS Health's payout ratio is 63.48%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CVS. Bell Investment Advisors Inc lifted its stake in shares of CVS Health by 119.8% in the 1st quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator's stock worth $31,000 after acquiring an additional 248 shares during the period. Saudi Central Bank acquired a new stake in shares of CVS Health in the 1st quarter worth $34,000. Costello Asset Management INC lifted its stake in shares of CVS Health by 281.3% in the 1st quarter. Costello Asset Management INC now owns 572 shares of the pharmacy operator's stock worth $39,000 after acquiring an additional 422 shares during the period. Stone House Investment Management LLC acquired a new stake in shares of CVS Health in the 1st quarter worth $39,000. Finally, Stonebridge Financial Group LLC acquired a new stake in shares of CVS Health in the 4th quarter worth $28,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CVS. JPMorgan Chase & Co. lifted their price target on CVS Health from $80.00 to $81.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 18th. Piper Sandler lifted their price target on CVS Health from $72.00 to $74.00 and gave the stock an "overweight" rating in a research note on Friday, March 21st. Argus set a $77.00 price target on CVS Health in a research note on Tuesday, February 18th. Mizuho lifted their price target on CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of CVS Health in a research note on Tuesday, April 15th. Two research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, CVS Health currently has an average rating of "Moderate Buy" and a consensus target price of $74.75.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.